These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37127555)

  • 1. A systematic review of clinical trials of treatment regimens in HER2-amplified metastatic colorectal cancer.
    Sur D; Lungulescu C; Dumitrescu EA; Afrăsânie V; Spînu Ș; Lungulescu CV; Schmoll HJ
    Expert Rev Anticancer Ther; 2023 Jun; 23(6):633-641. PubMed ID: 37127555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab-containing regimens for metastatic breast cancer.
    Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes.
    Bekaii-Saab TS; Lach K; Hsu LI; Siadak M; Stecher M; Ward J; Beckerman R; Strickler JH
    Oncologist; 2023 Oct; 28(10):885-893. PubMed ID: 37463037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
    Meric-Bernstam F; Hurwitz H; Raghav KPS; McWilliams RR; Fakih M; VanderWalde A; Swanton C; Kurzrock R; Burris H; Sweeney C; Bose R; Spigel DR; Beattie MS; Blotner S; Stone A; Schulze K; Cuchelkar V; Hainsworth J
    Lancet Oncol; 2019 Apr; 20(4):518-530. PubMed ID: 30857956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual HER2 Targeted Therapy With Pyrotinib and Trastuzumab in Refractory HER2 Positive Metastatic Colorectal Cancer: A Result From HER2-FUSCC-G Study.
    Chang J; Xu M; Wang C; Huang D; Zhang Z; Chen Z; Zhu X; Li W
    Clin Colorectal Cancer; 2022 Dec; 21(4):347-353. PubMed ID: 35941028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A network meta-analysis on the efficacy of HER2-targeted agents in combination with taxane-containing regimens for treatment of HER2-positive metastatic breast cancer.
    Xie BJ; Zhu LN; Ma C; Li JB; Dong L; Zhu ZN; Ding T; Gu XS
    Breast Cancer; 2020 Mar; 27(2):186-196. PubMed ID: 31529262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment Strategies for HER2-Positive Metastatic Colorectal Cancer].
    Yoshikawa A; Nakamura Y
    Gan To Kagaku Ryoho; 2023 Jul; 50(7):763-767. PubMed ID: 37496217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer.
    Sandhu J; Wang C; Fakih M
    J Natl Compr Canc Netw; 2020 Feb; 18(2):116-119. PubMed ID: 32023524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.
    Richman SD; Southward K; Chambers P; Cross D; Barrett J; Hemmings G; Taylor M; Wood H; Hutchins G; Foster JM; Oumie A; Spink KG; Brown SR; Jones M; Kerr D; Handley K; Gray R; Seymour M; Quirke P
    J Pathol; 2016 Mar; 238(4):562-70. PubMed ID: 26690310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review.
    Vaghi C; Mauri G; Agostara AG; Patelli G; Pizzutilo EG; Nakamura Y; Yoshino T; Siena S; Sartore-Bianchi A
    Cancer Treat Rev; 2023 Jan; 112():102488. PubMed ID: 36410093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis.
    Kawalec P; Łopuch S; Mikrut A
    Clin Breast Cancer; 2015 Apr; 15(2):90-100.e1. PubMed ID: 25441421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Treatment Patterns in Patients With HER2-Amplified Metastatic Colorectal Cancer: A Clinical-Genomic Database Study.
    Strickler JH; Hsu LI; Wright P; Stecher M; Siadak MF; Palanca-Wessels MC; Yu J; Zhang N; Espenschied CR; Lang K; Bekaii-Saab TS
    J Natl Compr Canc Netw; 2023 Aug; 21(8):805-812.e1. PubMed ID: 37549907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting HER2 in Advanced Breast Cancer.
    Zhu X; Joy AA
    Methods Mol Biol; 2017; 1652():63-77. PubMed ID: 28791634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
    Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
    BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab Combined with Irinotecan in Patients with HER2-Positive Metastatic Colorectal Cancer: A Phase II Single-Arm Study and Exploratory Biomarker Analysis.
    Xu T; Wang X; Xin Y; Wang Z; Gong J; Zhang X; Li Y; Ji C; Sun Y; Zhao F; Huang D; Bai Y; Li J; Shen L
    Cancer Res Treat; 2023 Apr; 55(2):626-635. PubMed ID: 36550683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of HER2-targeted inhibitors for metastatic colorectal cancer with HER2-amplified: A meta-analysis.
    Gao M; Jiang T; Li P; Zhang J; Xu K; Ren T
    Pharmacol Res; 2022 Aug; 182():106330. PubMed ID: 35781058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Targeting HER2 in colorectal cancer].
    Spitzer E; Cervera P; André T; Cohen R
    Bull Cancer; 2023 Apr; 110(4):402-411. PubMed ID: 36870811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
    Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
    Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.